Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px
Document › Details

Bavarian Nordic A/S. (1/31/18). "Press Release: Bavarian Nordic Announces the Planned Departure of Chief Financial Officer, Ole Larsen". Copenhagen.

Organisation Organisation Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY)
  Group Bavarian Nordic (Group)
Products Product MVA-BN® technology (Modified Vaccinia Ankara)
  Product 2 Imvamune®
Persons Person Larsen, Ole (Bavarian Nordic 2008–2018 LEFT in 2018 as CFO)
  Person 2 Chaplin, Paul (Bavarian Nordic 201410 CEO)
     


Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that Ole Larsen, Executive Vice President and Chief Financial Officer will depart from the Company to pursue new opportunities. The planned transition will take place within 2018 once an appropriate candidate has been identified. Until such time, Mr. Larsen will continue in his current capacity. Mr. Larsen joined Bavarian Nordic in 2008.

“On behalf of the entire Company, I want to thank Ole for his significant contributions over the past 10 years. Ole has been instrumental in growing Bavarian Nordic into a well-diversified, fully integrated company, currently in one of its strongest financial positions in our history,” said Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic. “We thank him for his dedication and his willingness to work through a smooth transition to an appropriate replacement. We wish him all the very best in his future endeavors.”

The Company is now initiating a search for the position of Chief Financial Officer.


About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development of innovative and safe therapies against cancer and infectious diseases. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates intended to improve the health and quality of life for children and adults. We supply our IMVAMUNE® non-replicating smallpox vaccine to the U.S. Strategic National Stockpile and other government stockpiles. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Registration studies are currently underway in the U.S. In addition to our long-standing collaboration with the U.S. government on the development of IMVAMUNE® and other medical countermeasures, our infectious disease pipeline comprises a proprietary RSV program as well as vaccine candidates for Ebola, HPV, HBV and HIV, which are developed through a strategic partnership with Janssen. Additionally, in collaboration with the National Cancer Institute, we have developed a portfolio of active cancer immunotherapies, designed to alter the disease course by eliciting a robust and broad anti-cancer immune response while maintaining a favorable risk-benefit profile. Through multiple industry collaborations, we seek to explore the potential synergies of combining our immunotherapies with other immune-modulating agents, e.g. checkpoint inhibitors. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.


Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.


Contacts

Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43

Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271


Company Announcement no. 02 / 2018
Published on January 31, 2018, 17:03 CET

   
Record changed: 2018-02-08

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

More documents for Bavarian Nordic (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top